These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Kupelian PA; Katcher J; Levin HS; Klein EA Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811 [TBL] [Abstract][Full Text] [Related]
64. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115 [TBL] [Abstract][Full Text] [Related]
65. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536 [TBL] [Abstract][Full Text] [Related]
66. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506 [TBL] [Abstract][Full Text] [Related]
67. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. Corn BW; Winter K; Pilepich MV Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361 [TBL] [Abstract][Full Text] [Related]
68. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis. Lee WR; Hanks GE; Schultheiss TE; Corn BW; Hunt MA J Clin Oncol; 1995 Feb; 13(2):464-9. PubMed ID: 7531222 [TBL] [Abstract][Full Text] [Related]
69. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Taylor N; Kelly JF; Kuban DA; Babaian RJ; Pisters LL; Pollack A Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):755-63. PubMed ID: 12788182 [TBL] [Abstract][Full Text] [Related]
70. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Lee AK; Levy LB; Cheung R; Kuban D Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415 [TBL] [Abstract][Full Text] [Related]
71. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful? Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V Tumori; 2004; 90(2):201-7. PubMed ID: 15237583 [TBL] [Abstract][Full Text] [Related]
72. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539 [TBL] [Abstract][Full Text] [Related]
73. Combined modality treatment in the management of high-risk prostate cancer. Stock RG; Cahlon O; Cesaretti JA; Kollmeier MA; Stone NN Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1352-9. PubMed ID: 15275720 [TBL] [Abstract][Full Text] [Related]
74. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer. Valicenti RK; Chervoneva I; Gomella LG Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249 [TBL] [Abstract][Full Text] [Related]
75. The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer. Johnstone PA; Williams SR; Riffenburgh RH Prostate Cancer Prostatic Dis; 2004; 7(3):263-7. PubMed ID: 15289811 [TBL] [Abstract][Full Text] [Related]
76. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA. Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922 [TBL] [Abstract][Full Text] [Related]
77. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Miller N; Smolkin ME; Bissonette E; Theodorescu D Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361 [TBL] [Abstract][Full Text] [Related]
78. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Laverdière J; Gomez JL; Cusan L; Suburu ER; Diamond P; Lemay M; Candas B; Fortin A; Labrie F Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):247-52. PubMed ID: 9069293 [TBL] [Abstract][Full Text] [Related]
79. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Leibowitz RL; Tucker SJ Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729 [TBL] [Abstract][Full Text] [Related]
80. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Copp H; Bissonette EA; Theodorescu D Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]